Results from a Phase III Clinical Trial for Subcutaneous Infusion of...

Continuous subcutaneous infusion (CSCI) of levodopa/carbidopa prodrugs, foslevodopa/foscarbidopa, improved time without dyskinesia in patients with advanced Parkinson’s disease (PD) according to a...(PRWeb September 15, 2022)Read the full story at https://www.prweb.com/releases/results_from_a_phase_iii_clinical_trial_for_subcutaneous_infusion_of_foslevodopa_foscarbidopa/prweb18891204.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news